AKCA:NSD-Akcea Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.14

Change

0.00 (0.00)%

Market Cap

USD 1.84B

Volume

0.90M

Average Target Price

USD 18.15 (+0.06%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.91 (+1.46%)

USD69.69B 32.32 25.77
REGN Regeneron Pharmaceuticals, Inc

-4.15 (-0.73%)

USD63.99B 21.32 16.47
SGEN Seattle Genetics, Inc

-0.96 (-0.54%)

USD30.73B N/A N/A
MRNA Moderna, Inc

-0.95 (-1.38%)

USD27.16B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-2.44 (-2.09%)

USD25.55B 28.27 25.54
RPRX Royalty Pharma plc

+0.67 (+1.65%)

USD24.71B 33.37 9.15
GMAB Genmab A/S

+0.27 (+0.72%)

USD24.24B 25.60 2.90
BGNE BeiGene, Ltd

+7.49 (+2.94%)

USD23.25B N/A N/A
IMMU Immunomedics, Inc

-0.02 (-0.02%)

USD19.73B N/A N/A
INCY Incyte Corporation

+0.48 (+0.53%)

USD19.67B 47.64 35.20

ETFs Containing AKCA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.08% 55% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.08% 55% F 67% D+
Trailing 12 Months  
Capital Gain -17.32% 32% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.32% 32% F 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.54% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.54% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.99% N/A N/A N/A N/A
Risk Adjusted Return -1.29% N/A N/A N/A N/A
Market Capitalization 1.84B 83% B 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.91 24% F 26% F
Price/Book Ratio 3.85 52% F 33% F
Price / Cash Flow Ratio 8.24 9% F 35% F
EV/EBITDA 24.24 19% F 29% F
Management Effectiveness  
Return on Equity -9.80% 90% A- 42% F
Return on Invested Capital 8.75% 91% A- 76% C
Return on Assets -5.95% 90% A- 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.29 39% F 26% F
Short Percent 23.15% 6% F 9% F
Beta 1.46 52% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.